CN107604004A - Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof - Google Patents
Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof Download PDFInfo
- Publication number
- CN107604004A CN107604004A CN201710865225.7A CN201710865225A CN107604004A CN 107604004 A CN107604004 A CN 107604004A CN 201710865225 A CN201710865225 A CN 201710865225A CN 107604004 A CN107604004 A CN 107604004A
- Authority
- CN
- China
- Prior art keywords
- vtt
- promoter
- tkl
- tkr
- tracer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Tracer target practice plasmid disclosed by the invention for vaccinia virus Tiantan strain TK genes, including the carrier pMV that sets out, the upstream homologous recombination arm VTT TKL and downstream homologous recombination arm VTT TKR of vaccinia virus Tiantan strain TK genes, there is vaccinia virus early late phase promoter P11 and late promoter P7.5 between VTT TKL and VTT TKR, catenation sequence between promoter P11 and promoter P7.5 has two restriction enzyme sites, promoter P11 downstream and promoter P7.5 downstream include 1 multiple cloning sites, tracer gene Luciferase is inserted at multiple cloning sites after promoter P7.5, the nucleotide sequence of the tracer target practice plasmid is as shown in sequence 1.The tracer target practice plasmid of the present invention, solve the problems, such as that existing vaccinia virus recombinant can not analyze the distribution situation of virus in vivo.Present invention also offers the preparation method of above-mentioned tracer target practice plasmid.
Description
Technical field
The invention belongs to technical field of biological genetic engineering, and in particular to a kind of for vaccinia virus Tiantan strain TK genes
Tracer target practice plasmid, the invention further relates to the preparation method of the tracer target practice plasmid for being used for vaccinia virus Tiantan strain TK genes.
Background technology
Vaccinia virus (vaccinia virus, VACV) belongs to Poxviridae, orthopoxvirus, is a kind of tunicary double
Chain DNA virus, its genome are up to 200kbp.Carriers or oncolytic virus of the VACV as vaccine, compared to other viral vectors such as
Retrovirus, human herpes simplex vicus and adenovirus etc., there are many unique advantages.And VACV exterminates smallpox as the mankind
Vaccine, be up to century more than one in the application of human body, its security and validity are sufficiently verified in practice.Cause
This, VACV is considered as comparatively ideal oncolytic virus carrier.
Vaccinia virus Tiantan strain (Vaccinia virus Tian Tan, VACV-VTT) is the distinctive Strain in China, by
In region Slurry pump, the vaccinia virus for oncolytic virus transformation mainly includes:WR strains (Western reserve), Wei
Family name's strain (Wyeth or NYCBOH), Liszt's strain (Lister) and Copenhagen strain (Copenhagen), for the molten of VACV-VTT
The research of knurl effect is still few.In order to study and improve VACV-VTT oncolytic effect, need to be transformed by corresponding target practice plasmid
VACV-VTT.At present, more than 20 kinds that China has been built are mainly used in infection prevention for the target practice plasmid of vaccinia virus Tiantan strain
Property disease, and the recombinant virus built with this lacks tracking function, can not analyze the distribution situation of virus in vivo, especially exists
Distribution in tumour, the needs of current attenuation oncolytic virus research can not be met.
The content of the invention
It is an object of the invention to provide a kind of tracer target practice plasmid for vaccinia virus Tiantan strain TK genes, solve
Existing vaccinia virus recombinant can not analyze the distribution situation problem of virus in vivo.
Present invention also offers the preparation method of the above-mentioned tracer target practice plasmid for vaccinia virus Tiantan strain TK genes.
The first technical scheme of the present invention is:Tracer target practice matter for vaccinia virus Tiantan strain TK genes
Grain, include the upstream homologous recombination arm VTT-TKL and downstream homologous recombination of the carrier pMV that sets out, vaccinia virus Tiantan strain TK genes
Arm VTT-TKR, there is vaccinia virus early late phase promoter P11 and late promoter P7.5 between VTT-TKL and VTT-TKR, open
Catenation sequence between mover P11 and promoter P7.5 has two restriction enzyme sites, under promoter P11 downstream and promoter P7.5
Swim and include 1 multiple cloning sites (Multiple cloning site, MCS), inserted at the multiple cloning sites after promoter P7.5
Enter tracer gene Luciferase, the nucleotide sequence of the tracer target practice plasmid is as shown in sequence 1.
The characteristics of the first technical scheme of the invention, also resides in,
The carrier pMV that sets out includes Escherichia coli replication origin pUC ori and amicillin resistance selection markers.
Promoter P11 and the order of promoter P7.5 promotor genes expression are on the contrary, promoter P11 be reverse starting, startup
Sub- P7.5 starts to be positive.
Second of technical scheme of the present invention be:Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes
Preparation method, specifically implement according to following steps:
Step 1:Engineer and synthetic promoter P7.5 and promoter P11 sequences and two multiple cloning sites sequences, and
It is cloned into pMV carriers, forms pMV-PRO plasmids;Synthetic primer is designed, PCR obtains upstream homologous recombination arm VTT-TKL with
Swim homologous recombination arm VTT-TKR and tracer gene Luciferase fragments;
Step 2:By the pMV-PRO plasmids obtained in step 1 and VTT-TKR fragments respectively after BamHI/KpnI double digestions
Purifying recovery, the fragment of recovery is attached, converted, interstitial granules pMV-VTTTKR in acquisition;
Step 3:The VTT-TKL fragments obtained in the pMV-VTTTKR plasmids and step 1 that are obtained in step 2 are passed through respectively
Recovery is purified after PstI/SalI double digestions, the fragment of recovery is attached, converted, obtains target practice plasmid pMV-VTTTK;
Step 4:The Luciferase fragments obtained in the pMV-VTTTK plasmids and step 1 that are obtained in step 3 are passed through respectively
Recovery is purified after EcoRI/BamHI double digestions, the fragment of recovery is attached, converted, obtains tracer target practice plasmid pMV-
VTTTK-Luc。
The characteristics of second of technical scheme of the invention, also resides in,
The primer that synthesis is designed in step 1 specifically includes following three pairs of primers:
Expand VTT-TKR primer pair:
Forward primer VTT-TKR-F:5’-CGGGATCCGGCTTCCTTTTCTAAACGATTGG-3’;
Reverse primer VTT-TKR-R:5’-GGGGTACCGAGTCAGTCTCATGTTCTCACCG-3’;
Expand VTT-TKL primer pair:
Forward primer VTT-TKL-F:5’-AACTGCAGACAGATATTCCGACAAAGGATTG-3’;
Reverse primer VTT-TKL-R:5’-ACGCGTCGACATCAACTGAATATGTCCGCCG-3’;
Expand the primer pair of Luciferase genes:
Luc-F:5’-GGAATTCGCCACCATGGAAGACGCCA-3’;
Luc-R:5’-CGGGATCCTTACACGGCGATCTTTCCGC-3’。
Upstream homologous recombination arm VTT-TKL and downstream homologous recombination arm VTT-TKR and tracer gene are obtained in step 1
Luciferase's comprises the following steps that:
1) wild type VACV-VTT genomic DNAs are extracted;
2) using VACV-VTT genomic DNAs template, carried by primer PCR of VTT-TKR-F/VTT-TKR-R
The VTT-TKR of BamHI/KpnI restriction enzyme sites, obtained using VTT-TKL-F/VTT-TKL-R as primer PCR and carry PstI/SalI enzymes
The VTT-TKL of enzyme site;Using p-EGFP-Luc plasmids as template, obtained using Luc-F/Luc-R as primer PCR and carry EcoRI/
The Luciferase genetic fragments of BamHI restriction enzyme sites;
3) PCR primer obtains upstream homologous recombination arm VTT-TKL and downstream respectively through agarose gel electrophoresis and glue reclaim
Homologous recombination arm VTT-TKR and tracer gene Luciferase fragments.
The invention has the advantages that
(1) tracer target practice plasmid of the present invention includes Luciferase genes, the TK bases of targeting knock out vaccinia virus Tiantan strain
The homologous recombination arm of cause, the vaccinia virus recombinant the Temple of Heaven strain of the attenuation with traceability can be prepared, and TK gene delections can
For recombinant celo virus;
(2) tracer target practice plasmid of the present invention includes the distinctive early late phase promoter and late promoter of bovine vaccine disease, not
It is different with the expression quantity of the foreign gene under promoter, can meet the needs of different foreign gene requirements are different, two promoters
Between restriction enzyme site can be inserted into new expression casette be used for express more foreign genes;
(3) the vaccinia virus recombinant the Temple of Heaven strain that tracer target practice plasmid of the present invention is prepared, can analyze oncolytic vaccinia virus and exist
Internal distribution situation, the distribution especially in tumour, it is that vaccinia virus researches and develops live vaccine and tumor biotherapy as carrier
Provide good tool.
Brief description of the drawings
Fig. 1 is the schematic diagram of the tracer target practice plasmid for vaccinia virus Tiantan strain TK genes of the present invention;
Fig. 2 is promoter and polyclonal position in the tracer target practice plasmid for vaccinia virus Tiantan strain TK genes of the invention
The schematic diagram of point;
Fig. 3 is the construction step schematic diagram of the tracer target practice plasmid for vaccinia virus Tiantan strain TK genes of the present invention;
Fig. 4 is the digestion qualification figure of the tracer target practice plasmid for vaccinia virus Tiantan strain TK genes of the present invention.
Embodiment
Below in conjunction with the accompanying drawings and embodiment the present invention is described in detail.It is it should be appreciated that described herein
Specific embodiment only to explain the present invention, be not intended to limit the present invention.
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material, reagent used in following embodiments, unless otherwise specified, are commercially obtained.
The genomic dna sequence of wild vaccinia virus Tiantan strain is No. GenBank sequence for being AF095689.1 in the present invention
Arrange (VRL 14-FEB-2000).
Wild-type vaccinia strain the Temple of Heaven strain in following examples is real in Xi'an Medical University's molecule virus and virological immunology
Test room (this laboratory, similarly hereinafter) preservation.Plasmid p-EGFP-Luc is by this Laboratories Accession.Plasmid pMV is carried by Huada gene company
For.
The invention provides a kind of tracer target practice plasmid for vaccinia virus Tiantan strain TK genes, its ideograph such as Fig. 1
Shown, its sequence is shown in sequence 1, including the carrier pMV that sets out, and it includes Escherichia coli replication origin pUC ori and ammonia benzyl is blue or green
Chloramphenicol resistance selection markers, the upstream homologous recombination of propagation and screening, vaccinia virus Tiantan strain TK genes for recombinant plasmid
Arm VTT-TKL and the TK genes both sides of downstream homologous recombination arm VTT-TKR, VTT-TKL and VTT-TKR and vaccinia virus Tiantan strain
Sequence homology, can target remove vaccinia virus Tiantan strain TK genes, have vaccinia virus between VTT-TKL and VTT-TKR
Early late phase promoter P11 and late promoter P7.5, the catenation sequence between promoter P11 and promoter P7.5 have two digestions
Site (MCS1 and MCS2), new expression cassette, promoter P11 downstream and promoter P7.5 downstream Jun Bao can be added here
Containing 1 multiple cloning sites, tracer gene Luciferase, Luciferase base is inserted at the multiple cloning sites after promoter P7.5
Reason P7.5 starts expression, recombinant virus is had traceability, other foreign genes is can be inserted into after promoter P11, for carrying
The Suppressive effect of high vaccinia virus Tiantan strain, Luciferase genetic fragments can be plugged under late promoter P7.5, can also insert
Enter under early late phase P11 promoters, line replacement can be entered according to different foreign gene demands difference.
Promoter P11 and the order of promoter P7.5 promotor genes expression are on the contrary, promoter P11 be reverse starting, startup
Sub- P7.5 starts to be positive;The restriction enzyme site that 2 multiple cloning sites in above-mentioned promoter downstream include is different.
The present invention is used for the tracer target practice plasmid pMV-VTTTK-Luc building process of vaccinia virus Tiantan strain TK genes:People
Promoter P11, P7.5 and multiple cloning sites sequence (i.e. the 1-417 positions of sequence 2, name that work synthesis tracer target practice plasmid includes
For P&MCS) and be inserted into the carrier pMV that sets out, form pMV-PRO plasmids;By the DNA sequence dna of wild vaccinia virus Tiantan strain
80725-81559 positions (i.e. the 1-835 positions of sequence 3, be named as VTT-TKR) and 79441-80319 positions (the i.e. 1- of sequence 4
879, it is named as VTT-TKL) pMV-PRO plasmids are successively cloned into, obtain including vaccinia virus Tiantan strain TK gene left and right sides
The target practice plasmid pMV-VTTTK of homologous recombination arm;Luciferase genes are inserted between multiple cloning sites after P7.5 promoters
Sequence (i.e. the 1-1659 positions of sequence 5, be named as Lucifefase, abbreviation Luc), obtain tracer target practice plasmid pMV-VTTTK-
Luc。
Concrete operations are as follows:
1. engineer and synthetic promoter and multiple cloning sites sequence
Vaccinia virus early late phase promoter P11 and late promoter P7.5 is selected, and screens suitable restriction endonuclease identification sequence
Row form multiple cloning sites (MCS).Promoter P11 is reverse starting, and promoter P7.5 starts to be positive, respectively positioned at people's process
The both ends of row, MCS1 are located at P11 downstream, and MCS2 is located at P7.5 downstream, designs catenation sequence between two promoters, make two
Kept at a distance between promoter, restriction enzyme site SacI and SpeI are designed with catenation sequence, send the artificial sequence of design to Hua Da base
Because company is synthesized, and it is cloned into pMV carriers, forms pMV-PRO plasmids.What initiator sequence and multiple cloning sites included
Restriction enzyme site is as shown in Figure 2.
2. design of primers and synthesis
(1) VTT-TKR primer pair is expanded:
Forward primer VTT-TKR-F:5’-CGGGATCCThe GGCTTCCTTTTCTAAACGATTGG-3 ' (front portions of underscore
It is divided into protection base, underscore part is BamHI endonuclease recognition sequences, and sequence is the 1-23 positions of sequence 3 thereafter)
Reverse primer VTT-TKR-R:5’-GGGGTACCThe GAGTCAGTCTCATGTTCTCACCG-3 ' (front portions of underscore
It is divided into protection base, underscore part is KpnI endonuclease recognition sequences, and sequence is the anti-of the 813-835 positions of sequence 3 thereafter
To complementary series)
(2) VTT-TKL primer pair is expanded:
Forward primer VTT-TKL-F:5’-AACTGCAGThe ACAGATATTCCGACAAAGGATTG-3 ' (front portions of underscore
It is divided into protection base, underscore part is PstI endonuclease recognition sequences, and sequence is the 1-23 positions of sequence 4 thereafter)
Reverse primer VTT-TKL-R:5’-ACGCGTCGACThe ATCAACTGAATATGTCCGCCG-3 ' (front portions of underscore
It is divided into protection base, underscore part is SalI endonuclease recognition sequences, and sequence is the anti-of the 759-879 positions of sequence 4 thereafter
To complementary series)
(3) primer pair of Luciferase genes is expanded:
Luc-F:5’-GGAATTC(forward part of underscore is protection base to GCCACCATGGAAGACGCCA-3 ', lower stroke
Line part is EcoRI endonuclease recognition sequences, and sequence is the 1-19 positions of sequence 5 thereafter)
Luc-R:5’-CGGGATCC(forward part of underscore is protection alkali to CGGGTTACACGGCGATCTTTCCGC-3 '
Base, underscore part are BamHI endonuclease recognition sequences, and sequence is the reverse complemental sequence of the 1640-1659 positions of sequence 5 thereafter
Row)
3. the acquisition of homologous recombination arm VTT-TKR and VTT-TKL and tracer gene Luciferase DNA fragmentation
(1) wild type VACV-VTT genomic DNAs are extracted:Using the viral genome extracts kit of Biomiga companies
Viral DNA is extracted, is operated by the specification provided in kit;
(2) using VACV-VTT genomic DNAs template, carried by primer PCR of VTT-TKR-F/VTT-TKR-R
The VTT-TKR of BamHI/KpnI restriction enzyme sites, obtained using VTT-TKL-F/VTT-TKL-R as primer PCR and carry PstI/SalI enzymes
The VTT-TKL of enzyme site;Using p-EGFP-Luc plasmids as template, obtained using Luc-F/Luc-R as primer PCR and carry EcoRI/
The Luciferase genetic fragments of BamHI restriction enzyme sites;
PCR reaction systems are:DNA 1 μ l, dNTP mix (2.5mM) 1 μ l, the μ l of forward primer (10 μM) 2, reverse primer
The μ l of 10 μ l, PrimeSTAR HS archaeal dna polymerases of (10 μM) 2 μ l, 5 × PrimeSTAR buffer 0.5, add DEPC water to totality
50 μ l of product.
PCR reaction conditions are:98 DEG C of pre-degeneration 30s;98 DEG C of denaturation 10s, 60 DEG C of annealing 15s, 72 DEG C of extension 1min/kb,
Circulation 30 times;72 DEG C extend 5 minutes, are finally placed in 4 DEG C of preservations;
(3) PCR fragment reclaims:For PCR primer through 1.5% agarose gel electrophoresis, it is 851bp, VTT- to see figure VTT-TKR
TKL is 897bp, Luciferase 1678bp, gel extraction purpose band, obtains VTT-TKR, VTT-TKL and
Luciferase DNA fragmentation.
4. tracer target practice plasmid pMV-VTTTK-Luc structure, flow are as shown in Figure 3.
(1) pMV-PRO plasmids and VTT-TKR fragments purify recovery after BamHI/KpnI double digestions respectively, by recovery
Fragment is attached, converted, interstitial granules pMV-VTTTKR in acquisition;
(2) pMV-VTTTKR plasmids and VTT-TKL fragments purify recovery after PstI/SalI double digestions respectively, will reclaim
Fragment be attached, convert, obtain target practice plasmid pMV-VTTTK;
(3) pMV-VTTTK plasmids and Luciferase fragments purify recovery after EcoRI/BamHI double digestions respectively, will
The fragment of recovery is attached, converted, and obtains tracer target practice plasmid pMV-VTTTK-Luc.
Each of the above walks plasmid construction, carries out corresponding digestion identification, digestion qualification figure as shown in Figure 4, wherein M is
MarkerIII.A:PMV-VTTTKR is through BamHI/KpnI digestion qualification figures;B:PMV-VTTTK identifies through PstI/SalI digestions
Figure;C:PMV-VTTTK-Luc is through EcoRI/BamHI digestion qualification figures.PMV-VTTTKR should occur through BamHI/KpnI double digestions
845bp and the bar segments of 2511bp two, digestion result is with expected consistent, and digestion result is as shown in Figure 4 A;PMV-VTTTK is through PstI/
SalI double digestions, 881bp and the bar segments of 3348bp two should occur, digestion result is with expected consistent, and digestion result is as shown in Figure 4 B;
PMV-VTTTK-Luc 1669bp and the bar segments of 4193bp two, digestion result and expection should occur through EcoRI/BamHI double digestions
Unanimously, digestion result as shown in Figure 4 C, finally, the tracer target practice plasmid pMV-VTTTK- for vaccinia virus Tiantan strain TK genes
Luc is successfully constructed.
Other foreign genes are can be inserted into after promoter P11, for improving the Suppressive effect of vaccinia virus Tiantan strain, are opened
There are two restriction enzyme sites SacI and SpeI on catenation sequence between mover P11 and P7.5, can add here according to demand new
Expression cassette to express more foreign genes.
During present invention work, homology arm VTT-TKL and VTT-TKR and Wild-type vaccinia strain the Temple of Heaven strain TK genes both sides
Homologous recombination occurs for sequence, the vaccinia virus recombinant the Temple of Heaven strain formed and knock out TK genes, expressed Lucifefase genes,
The reaction of Luciferase produces chemiluminescences produces bioluminescence, plays tracking function.
<110>Xi'an Medical University
<120>Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof
<130>Nothing
<210>1
<211>5862
<212>DNA
<213>pMV-VTTTK-Luc
<400>1
AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA AAGTGCCACC TGACGTCTAA 60
GAAACCATTA TTATCATGAC ATTAACCTAT AAAAATAGGC GTATCACGAG GCCCTTTCGT 120
TGTAAAACGA CGGCCAGTCG AACCACGCAA TGCGTCTCGA TCCGCAGTGT CTTGCGTCTC 180
TTTACTGCAG ACAGATATTC CGACAAAGGA TTGATTACTA TAAATGGAGA ATGTTCCTAA 240
TGTATACTTT AATCCTGTGT TTATAGAGCC CACGTTTAAA CATTCTTTAT TAAGTGTTTA 300
TAAACACAGA TTAATAGTTT TATTTGAAGT ATTCGTTGTA TTCATTCTAA TATATGTATT 360
TTTTAGATCT GAATTAAATA TGTTCTTCAT GCCTAAACGA AAAATACCCG ATCCTATTGA 420
TAGATTACGA CGTGCTAATC TAGCGTGTGA AGACGATAAA TTAATGATCT ATGGATTACC 480
ATGGATGACA ACTCAAACAT CTGCGTTATC AATAAATAGT AAACCGATAG TGTATAAAGA 540
TTGTGCAAAG CTTTTGCGAT CAATAAATGG ATCACAACCA GTATCTCTTA ACGATGTTCT 600
TCGCAGATGA TGATTCATTT TTTAAGTATT TGGCTAGTCA AGATGATGAA TCTTCATTAT 660
CTGATATATT GCAAATCACT CAATATCTAG ACTTTCTGTT ATTATTATTG ATCCAATCAA 720
AAAATAAATT AGAAGCCGTG GGTCATTGTT ATCAATCTCT TTCAGAGGAA TACAGACAAT 780
TGACAAAATT CACAGACTCT CAAGATTTTA AAAAACTGTT TAACAAGGTC CCTATTGTTA 840
CAGATGGAAG GGTCAAACTT AATAAAGGAT ATTTGTTCGA CTTTGTGATT AGTTTGATGC 900
GATTCAAAAA AGAATCCTCT CTAGCTACCA CCGCAATAGA TCCTATTAGA TACATAGATC 960
CTCGTCGCGA TATCGCATTT TCTAACGTGA TGGATATATT AAAGTCGAAT AAAGTGAACA 1020
ATAATTAATT CTTTATTGTC ATCATGAACG GCGGACATAT TCAGTTGATG TCGACAAGCT 1080
TCAACTGTCC ATGGGCCCGC GGCCGCTCGA GCATCTGGTA ATTTATAGCA TAGAAAAAAA 1140
CAAAATGAAA TTCTACTATA TTTTTACATA CATATATTCT AAATATGAAA GTGGTGATTG 1200
TGACTAGCGT AGCATCGCTC ATCTATATAC TATATAGTAA TACCAATAGA GCTCAAGACT 1260
ACGACTAGTA AACTGATACA ATCTCTTATA TGTGGGTAAT GTTCTCGATG TCGATAGCCA 1320
TATGCCCGGT AGTTGCGATA TACATAAACT GATCACTAAT TCCAAACCCA CCCGCTTTTT 1380
ATAGTAAGTT TTTCACCCAT AAATAATAAA TACAATGGAA TTCGCCACCA TGGAAGACGC 1440
CAAAAACATA AAGAAAGGCC CGGCGCCATT CTATCCGCTG GAAGATGGAA CCGCTGGAGA 1500
GCAACTGCAT AAGGCTATGA AGAGATACGC CCTGGTTCCT GGAACAATTG CTTTTACAGA 1560
TGCACATATC GAGGTGGACA TCACTTACGC TGAGTACTTC GAAATGTCCG TTCGGTTGGC 1620
AGAAGCTATG AAACGATATG GGCTGAATAC AAATCACAGA ATCGTCGTAT GCAGTGAAAA 1680
CTCTCTTCAA TTCTTTATGC CGGTGTTGGG CGCGTTATTT ATCGGAGTTG CAGTTGCGCC 1740
CGCGAACGAC ATTTATAATG AACGTGAATT GCTCAACAGT ATGGGCATTT CGCAGCCTAC 1800
CGTGGTGTTC GTTTCCAAAA AGGGGTTGCA AAAAATTTTG AACGTGCAAA AAAAGCTCCC 1860
AATCATCCAA AAAATTATTA TCATGGATTC TAAAACGGAT TACCAGGGAT TTCAGTCGAT 1920
GTACACGTTC GTCACATCTC ATCTACCTCC CGGTTTTAAT GAATACGATT TTGTGCCAGA 1980
GTCCTTCGAT AGGGACAAGA CAATTGCACT GATCATGAAC TCCTCTGGAT CTACTGGTCT 2040
GCCTAAAGGT GTCGCTCTGC CTCATAGAAC TGCCTGCGTG AGATTCTCGC ATGCCAGAGA 2100
TCCTATTTTT GGCAATCAAA TCATTCCGGA TACTGCGATT TTAAGTGTTG TTCCATTCCA 2160
TCACGGTTTT GGAATGTTTA CTACACTCGG ATATTTGATA TGTGGATTTC GAGTCGTCTT 2220
AATGTATAGA TTTGAAGAAG AGCTGTTTCT GAGGAGCCTT CAGGATTACA AGATTCAAAG 2280
TGCGCTGCTG GTGCCAACCC TATTCTCCTT CTTCGCCAAA AGCACTCTGA TTGACAAATA 2340
CGATTTATCT AATTTACACG AAATTGCTTC TGGTGGCGCT CCCCTCTCTA AGGAAGTCGG 2400
GGAAGCGGTT GCCAAGAGGT TCCATCTGCC AGGTATCAGG CAAGGATATG GGCTCACTGA 2460
GACTACATCA GCTATTCTGA TTACACCCGA GGGGGATGAT AAACCGGGCG CGGTCGGTAA 2520
AGTTGTTCCA TTTTTTGAAG CGAAGGTTGT GGATCTGGAT ACCGGGAAAA CGCTGGGCGT 2580
TAATCAAAGA GGCGAACTGT GTGTGAGAGG TCCTATGATT ATGTCCGGTT ATGTAAACAA 2640
TCCGGAAGCG ACCAACGCCT TGATTGACAA GGATGGATGG CTACATTCTG GAGACATAGC 2700
TTACTGGGAC GAAGACGAAC ACTTCTTCAT CGTTGACCGC CTGAAGTCTC TGATTAAGTA 2760
CAAAGGCTAT CAGGTGGCTC CCGCTGAATT GGAATCCATC TTGCTCCAAC ACCCCAACAT 2820
CTTCGACGCA GGTGTCGCAG GTCTTCCCGA CGATGACGCC GGTGAACTTC CCGCCGCCGT 2880
TGTTGTTTTG GAGCACGGAA AGACGATGAC GGAAAAAGAG ATCGTGGATT ACGTCGCCAG 2940
TCAAGTAACA ACCGCGAAAA AGTTGCGCGG AGGAGTTGTG TTTGTGGACG AAGTACCGAA 3000
AGGTCTTACC GGAAAACTCG ACGCAAGAAA AATCAGAGAG ATCCTCATAA AGGCCAAGAA 3060
GGGCGGAAAG ATCGCCGTGT AACCCGGGAT CCGGCTTCCT TTTCTAAACG ATTGGGTGAG 3120
GAAACCGAGA TAGAAATAAT AGGAGGTAAT GATATGTATC AATCGGTGTG TAGAAAGTGT 3180
TACATCGACT CATAATATTA TATTTTTTAT CTAAAAAACT AAAAATAAAC ATTGATTAAA 3240
TTTTAATATA ATACTTAAAA ATGGATGTTG TGTCGTTAGA TAAACCGTTT ATGTATTTTG 3300
AGGAAATTGA TAATGAGTTA GATTACGAAC CAGAAAGTGC AAATGAGGTC GCAAAAAAAC 3360
TGCCGTATCA AGGACAGTTA AAACTATTAC TAGGAGAATT ATTTTTTCTT AGTAAGTTAC 3420
AGCGACACGG TATATTAGAT GGTGCCACCG TAGTGTATAT AGGATCTGCT CCCGGTACAC 3480
ATATACGTTA TTTGAGAGAT CATTTCTATA ATTTAGGAGT GATCATCAAA TGGATGCTAA 3540
TTGACGGCCG CCATCATGAT CCTATTTTAA ATGGATTGCG TGATGTGACT CTAGTGACTC 3600
GGTTCGTTGA TGAGGAATAT CTACGATCCA TCAAAAAACA ACTGCATCCT TCTAAGATTA 3660
TTTTAATTTC TGATGTGAGA TCCAAACGAG GAGGAAATGA ACCTAGTACG GCGGATTTAC 3720
TAAGTAATTA CGCTCTACAA AATGTCATGA TTAGTATTTT AAACCCCGTG GCATCTAGTC 3780
TTAAATGGAG ATGCCCGTTT CCAGATCAAT GGATCAAGGA CTTTTATATC CCACACGGTA 3840
ATAAAATGTT ACAACCTTTT GCTCCTTCAT ATTCAGCTGA AATGAGATTA TTAAGTATTT 3900
ATACCGGTGA GAACATGAGA CTGACTCGGT ACCTAAAGAG ACGGAGTCAC TGCCAACCGA 3960
GACGGTCATA GCTGTTTCCT GTGTGCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 4020
GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT ACCCACAGAA 4080
TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC CAGGAACCGT 4140
AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA GCATCACAAA 4200
AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT 4260
CCCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 4320
TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG TAGGTATCTC 4380
AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC ACGAACCCCC CGTTCAGCCC 4440
GACCGCTGCG CCTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG ACACGACTTA 4500
TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT 4560
ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 4620
TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG ATCCGGCAAA 4680
CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC GCGCAGAAAA 4740
AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA GTGGAACGAA 4800
AACTCACGTT AAGGGATTTT GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT 4860
TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 4920
AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT TCGTTCATCC 4980
ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT ACCATCTGGC 5040
CCCAGTGCTG CAATAATACC GCGGGACCCA CGCTCACCGG CTCCAGATTT ATCAGCAATA 5100
AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC 5160
CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 5220
AACGTTGTTG CCATCGCTAC AGGCATCGTG GTATCACGCT CGTCGTTTGG TATGGCTTCA 5280
TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT GCGCAAAAAA 5340
GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC CGTGTTATCA 5400
CTCATGGTTA TGGCAGCACT ACATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT 5460
TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 5520
TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC TTTAAAAGTG 5580
CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA GGATCTTACC GCTGTTGAGA 5640
TCCAGTTCGA TGTAACCCAC TCGTGCACCC AACTGATCTT CAGCATCTTT TACTTTCACC 5700
AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG 5760
ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 5820
GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AG 5862
<210>2
<211>417
<212>DNA
<213>P&MCS
<400>2
TTACTGCAGG CATGCGTCGA CAAGCTTCAA CTGTCCATGG GCCCGCGGCC GCTCGAGCAT 60
CTGGTAATTT ATAGCATAGA AAAAAACAAA ATGAAATTCT ACTATATTTT TACATACATA 120
TATTCTAAAT ATGAAAGTGG TGATTGTGAC TAGCGTAGCA TCGCTCATCT ATATACTATA 180
TAGTAATACC AATAGAGCTC AAGACTACGA CTAGTAAACT GATACAATCT CTTATATGTG 240
GGTAATGTTC TCGATGTCGA TAGCCATATG CCCGGTAGTT GCGATATACA TAAACTGATC 300
ACTAATTCCA AACCCACCCG CTTTTTATAG TAAGTTTTTC ACCCATAAAT AATAAATACA 360
ATGGAATTCG CGCGCGATAT CGGCGCCTAT TCGTCTAGAG GATCCCCGGG TACCTAA 417
<210>3
<211>835
<212>DNA
<213>VTT-TKR
<400>3
GGCTTCCTTT TCTAAACGAT TGGGTGAGGA AACCGAGATA GAAATAATAG GAGGTAATGA 60
TATGTATCAA TCGGTGTGTA GAAAGTGTTA CATCGACTCA TAATATTATA TTTTTTATCT 120
AAAAAACTAA AAATAAACAT TGATTAAATT TTAATATAAT ACTTAAAAAT GGATGTTGTG 180
TCGTTAGATA AACCGTTTAT GTATTTTGAG GAAATTGATA ATGAGTTAGA TTACGAACCA 240
GAAAGTGCAA ATGAGGTCGC AAAAAAACTG CCGTATCAAG GACAGTTAAA ACTATTACTA 300
GGAGAATTAT TTTTTCTTAG TAAGTTACAG CGACACGGTA TATTAGATGG TGCCACCGTA 360
GTGTATATAG GATCTGCTCC CGGTACACAT ATACGTTATT TGAGAGATCA TTTCTATAAT 420
TTAGGAGTGA TCATCAAATG GATGCTAATT GACGGCCGCC ATCATGATCC TATTTTAAAT 480
GGATTGCGTG ATGTGACTCT AGTGACTCGG TTCGTTGATG AGGAATATCT ACGATCCATC 540
AAAAAACAAC TGCATCCTTC TAAGATTATT TTAATTTCTG ATGTGAGATC CAAACGAGGA 600
GGAAATGAAC CTAGTACGGC GGATTTACTA AGTAATTACG CTCTACAAAA TGTCATGATT 660
AGTATTTTAA ACCCCGTGGC ATCTAGTCTT AAATGGAGAT GCCCGTTTCC AGATCAATGG 720
ATCAAGGACT TTTATATCCC ACACGGTAAT AAAATGTTAC AACCTTTTGC TCCTTCATAT 780
TCAGCTGAAA TGAGATTATT AAGTATTTAT ACCGGTGAGA ACATGAGACT GACTC 835
<210>4
<211>879
<212>DNA
<213>VTT-TKL
<400>4
ACAGATATTC CGACAAAGGA TTGATTACTA TAAATGGAGA ATGTTCCTAA TGTATACTTT 60
AATCCTGTGT TTATAGAGCC CACGTTTAAA CATTCTTTAT TAAGTGTTTA TAAACACAGA 120
TTAATAGTTT TATTTGAAGT ATTCGTTGTA TTCATTCTAA TATATGTATT TTTTAGATCT 180
GAATTAAATA TGTTCTTCAT GCCTAAACGA AAAATACCCG ATCCTATTGA TAGATTACGA 240
CGTGCTAATC TAGCGTGTGA AGACGATAAA TTAATGATCT ATGGATTACC ATGGATGACA 300
ACTCAAACAT CTGCGTTATC AATAAATAGT AAACCGATAG TGTATAAAGA TTGTGCAAAG 360
CTTTTGCGAT CAATAAATGG ATCACAACCA GTATCTCTTA ACGATGTTCT TCGCAGATGA 420
TGATTCATTT TTTAAGTATT TGGCTAGTCA AGATGATGAA TCTTCATTAT CTGATATATT 480
GCAAATCACT CAATATCTAG ACTTTCTGTT ATTATTATTG ATCCAATCAA AAAATAAATT 540
AGAAGCCGTG GGTCATTGTT ATCAATCTCT TTCAGAGGAA TACAGACAAT TGACAAAATT 600
CACAGACTCT CAAGATTTTA AAAAACTGTT TAACAAGGTC CCTATTGTTA CAGATGGAAG 660
GGTCAAACTT AATAAAGGAT ATTTGTTCGA CTTTGTGATT AGTTTGATGC GATTCAAAAA 720
AGAATCCTCT CTAGCTACCA CCGCAATAGA TCCTATTAGA TACATAGATC CTCGTCGCGA 780
TATCGCATTT TCTAACGTGA TGGATATATT AAAGTCGAAT AAAGTGAACA ATAATTAATT 840
CTTTATTGTC ATCATGAACG GCGGACATAT TCAGTTGAT 879
<210>5
<211>1659
<212>DNA
<213>Luciferase
<400>5
GCCACCATGG AAGACGCCAA AAACATAAAG AAAGGCCCGG CGCCATTCTA TCCGCTGGAA 60
GATGGAACCG CTGGAGAGCA ACTGCATAAG GCTATGAAGA GATACGCCCT GGTTCCTGGA 120
ACAATTGCTT TTACAGATGC ACATATCGAG GTGGACATCA CTTACGCTGA GTACTTCGAA 180
ATGTCCGTTC GGTTGGCAGA AGCTATGAAA CGATATGGGC TGAATACAAA TCACAGAATC 240
GTCGTATGCA GTGAAAACTC TCTTCAATTC TTTATGCCGG TGTTGGGCGC GTTATTTATC 300
GGAGTTGCAG TTGCGCCCGC GAACGACATT TATAATGAAC GTGAATTGCT CAACAGTATG 360
GGCATTTCGC AGCCTACCGT GGTGTTCGTT TCCAAAAAGG GGTTGCAAAA AATTTTGAAC 420
GTGCAAAAAA AGCTCCCAAT CATCCAAAAA ATTATTATCA TGGATTCTAA AACGGATTAC 480
CAGGGATTTC AGTCGATGTA CACGTTCGTC ACATCTCATC TACCTCCCGG TTTTAATGAA 540
TACGATTTTG TGCCAGAGTC CTTCGATAGG GACAAGACAA TTGCACTGAT CATGAACTCC 600
TCTGGATCTA CTGGTCTGCC TAAAGGTGTC GCTCTGCCTC ATAGAACTGC CTGCGTGAGA 660
TTCTCGCATG CCAGAGATCC TATTTTTGGC AATCAAATCA TTCCGGATAC TGCGATTTTA 720
AGTGTTGTTC CATTCCATCA CGGTTTTGGA ATGTTTACTA CACTCGGATA TTTGATATGT 780
GGATTTCGAG TCGTCTTAAT GTATAGATTT GAAGAAGAGC TGTTTCTGAG GAGCCTTCAG 840
GATTACAAGA TTCAAAGTGC GCTGCTGGTG CCAACCCTAT TCTCCTTCTT CGCCAAAAGC 900
ACTCTGATTG ACAAATACGA TTTATCTAAT TTACACGAAA TTGCTTCTGG TGGCGCTCCC 960
CTCTCTAAGG AAGTCGGGGA AGCGGTTGCC AAGAGGTTCC ATCTGCCAGG TATCAGGCAA 1020
GGATATGGGC TCACTGAGAC TACATCAGCT ATTCTGATTA CACCCGAGGG GGATGATAAA 1080
CCGGGCGCGG TCGGTAAAGT TGTTCCATTT TTTGAAGCGA AGGTTGTGGA TCTGGATACC 1140
GGGAAAACGC TGGGCGTTAA TCAAAGAGGC GAACTGTGTG TGAGAGGTCC TATGATTATG 1200
TCCGGTTATG TAAACAATCC GGAAGCGACC AACGCCTTGA TTGACAAGGA TGGATGGCTA 1260
CATTCTGGAG ACATAGCTTA CTGGGACGAA GACGAACACT TCTTCATCGT TGACCGCCTG 1320
AAGTCTCTGA TTAAGTACAA AGGCTATCAG GTGGCTCCCG CTGAATTGGA ATCCATCTTG 1380
CTCCAACACC CCAACATCTT CGACGCAGGT GTCGCAGGTC TTCCCGACGA TGACGCCGGT 1440
GAACTTCCCG CCGCCGTTGT TGTTTTGGAG CACGGAAAGA CGATGACGGA AAAAGAGATC 1500
GTGGATTACG TCGCCAGTCA AGTAACAACC GCGAAAAAGT TGCGCGGAGG AGTTGTGTTT 1560
GTGGACGAAG TACCGAAAGG TCTTACCGGA AAACTCGACG CAAGAAAAAT CAGAGAGATC 1620
CTCATAAAGG CCAAGAAGGG CGGAAAGATC GCCGTGTAA 1659
Claims (6)
1. the tracer target practice plasmid for vaccinia virus Tiantan strain TK genes, it is characterised in that including carrier pMV, the bovine vaccine of setting out
The upstream homologous recombination arm VTT-TKL and downstream homologous recombination arm VTT-TKR of viral the Temple of Heaven strain TK genes, VTT-TKL with
There is vaccinia virus early late phase promoter P11 and late promoter P7.5 between VTT-TKR, between promoter P11 and promoter P7.5
Catenation sequence have two restriction enzyme sites, promoter P11 downstream and promoter P7.5 downstream include 1 polyclonal position
Point, tracer gene Luciferase, the nucleotides sequence of the tracer target practice plasmid are inserted at the multiple cloning sites after promoter P7.5
Row are as shown in sequence 1.
2. it is used for the tracer target practice plasmid of vaccinia virus Tiantan strain TK genes as claimed in claim 1, it is characterised in that described
The carrier pMV that sets out includes Escherichia coli replication origin pUC ori and amicillin resistance selection markers.
3. it is used for the tracer target practice plasmid of vaccinia virus Tiantan strain TK genes as claimed in claim 1 or 2, it is characterised in that
The order of promoter P11 and promoter P7.5 promotor gene expression is on the contrary, promoter P11 is reverse starting, promoter
P7.5 starts to be positive.
4. being used for the preparation method of the tracer target practice plasmid of vaccinia virus Tiantan strain TK genes as claimed in claim 1, it is special
Sign is, specifically implements according to following steps:
Step 1:Engineer and synthetic promoter P7.5 and promoter P11 sequences and two multiple cloning sites sequences, and clone
Into pMV carriers, pMV-PRO plasmids are formed;Synthetic primer is designed, PCR obtains upstream homologous recombination arm VTT-TKL and downstream is same
Source recombinates arm VTT-TKR and tracer gene Luciferase fragments;
Step 2:The pMV-PRO plasmids obtained in step 1 and VTT-TKR fragments are purified after BamHI/KpnI double digestions respectively
Recovery, the fragment of recovery is attached, converted, interstitial granules pMV-VTTTKR in acquisition;
Step 3:By the VTT-TKL fragments obtained in the pMV-VTTTKR plasmids and step 1 that are obtained in step 2 respectively through PstI/
Recovery is purified after SalI double digestions, the fragment of recovery is attached, converted, obtains target practice plasmid pMV-VTTTK;
Step 4:The Luciferase fragments obtained in the pMV-VTTTK plasmids and step 1 that are obtained in step 3 are passed through respectively
Recovery is purified after EcoRI/BamHI double digestions, the fragment of recovery is attached, converted, obtains tracer target practice plasmid pMV-
VTTTK-Luc。
5. being used for the preparation method of the tracer target practice plasmid of vaccinia virus Tiantan strain TK genes as claimed in claim 4, it is special
Sign is that the primer that synthesis is designed in the step 1 specifically includes following three pairs of primers:
Expand VTT-TKR primer pair:
Forward primer VTT-TKR-F:5’-CGGGATCCGGCTTCCTTTTCTAAACGATTGG-3’;
Reverse primer VTT-TKR-R:5’-GGGGTACCGAGTCAGTCTCATGTTCTCACCG-3’;
Expand VTT-TKL primer pair:
Forward primer VTT-TKL-F:5’-AACTGCAGACAGATATTCCGACAAAGGATTG-3’;
Reverse primer VTT-TKL-R:5’-ACGCGTCGACATCAACTGAATATGTCCGCCG-3’;
Expand the primer pair of Luciferase genes:
Luc-F:5’-GGAATTCGCCACCATGGAAGACGCCA-3’;
Luc-R:5’-CGGGATCCTTACACGGCGATCTTTCCGC-3’。
6. being used for the preparation method of the tracer target practice plasmid of vaccinia virus Tiantan strain TK genes as claimed in claim 5, it is special
Sign is, upstream homologous recombination arm VTT-TKL and downstream homologous recombination arm VTT-TKR and tracer gene are obtained in the step 1
Luciferase's comprises the following steps that:
1) wild type VACV-VTT genomic DNAs are extracted;
2) using VACV-VTT genomic DNAs template, obtained using VTT-TKR-F/VTT-TKR-R as primer PCR and carry BamHI/
The VTT-TKR of KpnI restriction enzyme sites, obtained using VTT-TKL-F/VTT-TKL-R as primer PCR and carry PstI/SalI restriction enzyme sites
VTT-TKL;Using p-EGFP-Luc plasmids as template, obtained using Luc-F/Luc-R as primer PCR and carry EcoRI/BamHI enzymes
The Luciferase genetic fragments of enzyme site;
3) PCR primer obtains upstream homologous recombination arm VTT-TKL respectively and downstream is homologous through agarose gel electrophoresis and glue reclaim
Recombinate arm VTT-TKR and tracer gene Luciferase fragments.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710865225.7A CN107604004A (en) | 2017-09-22 | 2017-09-22 | Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710865225.7A CN107604004A (en) | 2017-09-22 | 2017-09-22 | Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107604004A true CN107604004A (en) | 2018-01-19 |
Family
ID=61061918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710865225.7A Pending CN107604004A (en) | 2017-09-22 | 2017-09-22 | Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107604004A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676814A (en) * | 2018-04-20 | 2018-10-19 | 西安医学院 | A kind of fluorescent marker shuttle vector of Tiantan strain vaccinia virus and preparation method thereof |
CN109750056A (en) * | 2019-01-07 | 2019-05-14 | 西安医学院 | Remove the target practice plasmid and preparation method thereof of the Temple of Heaven strain VGF gene |
CN109810953A (en) * | 2019-01-07 | 2019-05-28 | 西安彤盛生物科技有限公司 | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal TK gene and its preparation and application |
CN110157721A (en) * | 2019-01-07 | 2019-08-23 | 西安医学院 | A kind of tracer target practice plasmid of vaccinia virus Tiantan strain and preparation method thereof |
CN110205304A (en) * | 2019-01-07 | 2019-09-06 | 西安彤盛生物科技有限公司 | A kind of recombination the Temple of Heaven strain oncolytic vaccinia virus and preparation method and application |
CN110205307A (en) * | 2019-01-07 | 2019-09-06 | 西安彤盛生物科技有限公司 | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal VGF gene and preparation and application |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085564A2 (en) * | 2006-09-20 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and methods involving truncated recombinant seven g-protein coupled receptors |
CN102206679A (en) * | 2011-03-30 | 2011-10-05 | 中国人民解放军军事医学科学院军事兽医研究所 | Shuttle vector of vaccinia virus and its application |
CN103305478A (en) * | 2013-06-08 | 2013-09-18 | 中国人民解放军疾病预防控制所 | In-vivo imaging tracing system of vaccinia virus and application of system |
CN103305477A (en) * | 2013-06-08 | 2013-09-18 | 中国人民解放军疾病预防控制所 | GFP (Green Fluorescent Protein) tracing system of vaccinia virus and application of GFP tracing system |
CN105861558A (en) * | 2016-06-24 | 2016-08-17 | 西安医学院 | Vaccinia virus shuttle vector and preparation method and application thereof |
-
2017
- 2017-09-22 CN CN201710865225.7A patent/CN107604004A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008085564A2 (en) * | 2006-09-20 | 2008-07-17 | The Board Of Regents Of The University Of Texas System | Compositions and methods involving truncated recombinant seven g-protein coupled receptors |
CN102206679A (en) * | 2011-03-30 | 2011-10-05 | 中国人民解放军军事医学科学院军事兽医研究所 | Shuttle vector of vaccinia virus and its application |
CN103305478A (en) * | 2013-06-08 | 2013-09-18 | 中国人民解放军疾病预防控制所 | In-vivo imaging tracing system of vaccinia virus and application of system |
CN103305477A (en) * | 2013-06-08 | 2013-09-18 | 中国人民解放军疾病预防控制所 | GFP (Green Fluorescent Protein) tracing system of vaccinia virus and application of GFP tracing system |
CN105861558A (en) * | 2016-06-24 | 2016-08-17 | 西安医学院 | Vaccinia virus shuttle vector and preparation method and application thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676814A (en) * | 2018-04-20 | 2018-10-19 | 西安医学院 | A kind of fluorescent marker shuttle vector of Tiantan strain vaccinia virus and preparation method thereof |
CN109750056A (en) * | 2019-01-07 | 2019-05-14 | 西安医学院 | Remove the target practice plasmid and preparation method thereof of the Temple of Heaven strain VGF gene |
CN109810953A (en) * | 2019-01-07 | 2019-05-28 | 西安彤盛生物科技有限公司 | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal TK gene and its preparation and application |
CN110157721A (en) * | 2019-01-07 | 2019-08-23 | 西安医学院 | A kind of tracer target practice plasmid of vaccinia virus Tiantan strain and preparation method thereof |
CN110205304A (en) * | 2019-01-07 | 2019-09-06 | 西安彤盛生物科技有限公司 | A kind of recombination the Temple of Heaven strain oncolytic vaccinia virus and preparation method and application |
CN110205307A (en) * | 2019-01-07 | 2019-09-06 | 西安彤盛生物科技有限公司 | The recombination the Temple of Heaven strain oncolytic vaccinia virus of removal VGF gene and preparation and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107604004A (en) | Tracer target practice plasmid for vaccinia virus Tiantan strain TK genes and preparation method thereof | |
CN109777761B (en) | Construction and application of engineering bacteria for secretory expression of chitobiose deacetylase | |
Alting-Mees et al. | [42] pBluescriptII: Multifunctional cloning and mapping vectors | |
CN113862235B (en) | Chimeric enzyme and application and method thereof in one-step reaction synthesis of Cap0 mRNA in vitro | |
CN112225822B (en) | CAR-iNKT with high amplification, survival ability and tumor killing effect and application thereof | |
CN102002509B (en) | Escherichia coli-bacillus subtilis shuttle expression vector and application thereof | |
CN111239386B (en) | Screening method and application of small molecular compound for targeted inhibition of vitamin K-dependent gamma-glutamyl carboxylase | |
KR101614679B1 (en) | Chimeric strain of Porcine Reproductive and Respiratory Syndrome Virus | |
CN108718529B (en) | Mutant microorganism for producing L-cysteine and method for producing L-cysteine using the same | |
CN110944656A (en) | Novel polynucleotides encoding human FKRP proteins | |
WO1992017581A1 (en) | Mammalian expression vector | |
CN101463362B (en) | Expression vector for fusion expression of green fluorescent protein, construction method and use thereof | |
CN114032217A (en) | Novel coronavirus compound vaccine based on DNA vector and replicative vaccinia virus vector | |
KR20200086902A (en) | A vector for monitoring differentiation of neural cells and method for monitoring the differentiation into neural cells using the same | |
CN111239385B (en) | Screening method and application of small molecule compound for targeted inhibition of vitamin K epoxide reductase | |
CN114457113B (en) | Method for inhibiting haploid embryonic stem cell doubling | |
CN100429309C (en) | 100bp gradient ribonucleic acid molecular weight marker and its preparation | |
CN111560392B (en) | MiRNA expression vector and application thereof | |
CN101220374A (en) | Fowl pox virus double-gene expression carrier (PG7.5N) | |
KR102454110B1 (en) | Recombinant plasmids and mutant strains for screening inhibitors of ppGpp biosynthesis-related gene expression | |
CN108385170B (en) | Regulatory sequence library of Bacillus subtilis F4 promoter | |
CN111206024B (en) | Engineering bacterium for expressing pectate endo-hydrolase and application thereof | |
CN114277047B (en) | Application of high-throughput screening tool for obtaining effective NHEJ system from escherichia coli in escherichia coli gene editing | |
KR20120043657A (en) | Method for mass production of factor vii/viia | |
CN110115770B (en) | Novel target for preventing and treating viral hepatitis C, CRISPR-Cas9 targeting system and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180119 |